Physician profile

Scott D Skibo

Pulmonary Disease · Pinehurst, NC

NPI 1063431849

$229,279.61

in general payments reported to CMS, 2019-2025

17 companies · $1,220 in 2025

The $1,220 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$7,310.00
Travel and Lodging$935.09
Food and Beverage$373.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $90,673.91 2019-2021
Astrazeneca Pharmaceuticals LP $86,929.05 2019-2021
Covidien LP $31,059.62 2019-2020
Medtronic, INC. $14,280.00 2021-2025 Superlock
Viiv Healthcare Company $1,600.00 2019
Intuitive Surgical, INC. $1,427.10 2019-2025
Astrazeneca Uk Limited $1,011.00 2021
Ge Healthcare $953.15 2023
Ethicon INC. $332.03 2019-2021
Auris Health, INC. $220.71 2019
Noah Medical Corporation $200.52 2023-2025 Galaxy
Broncus Medical $177.07 2019
Healthmyne, INC. $154.05 2019
Boston Scientific Corporation $82.70 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $77.11 2022
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Gyrus Acmi, INC. $75.14 2019
Siemens Medical Solutions USA, INC. $26.45 2024 Cios Spin

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$2,040.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott D Skibo

$229,279.61

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,220 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/991591/scott-d-skibo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.